Premium
Moving Fecal Microbiota Transplantation Into the Mainstream
Author(s) -
Orenstein Robert,
Griesbach Cheryl L.,
DiBaise John K.
Publication year - 2013
Publication title -
nutrition in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.725
H-Index - 71
eISSN - 1941-2452
pISSN - 0884-5336
DOI - 10.1177/0884533613497516
Subject(s) - medicine , clostridium difficile , fecal bacteriotherapy , aka , intensive care medicine , transplantation , rescue therapy , feces , disease , antibiotics , library science , computer science , microbiology and biotechnology , biology , paleontology
In recent years, fecal microbiota transplantation (aka fecal transplantation, fecal bacteriotherapy, FMT) has become increasing utilized to treat recurrent and refractory Clostridium difficile infection (CDI). Almost 600,000 cases of CDI occur each year in the United States. Of these, an estimated 15,000 patients have a recurrence. The management of recurrent disease has been challenging for patients and clinicians. Increasingly, FMT has been recognized as an effective option for these patients. This article explores why FMT has reemerged as a practical therapeutic modality. In the process, the logistics by which the procedure is performed and the factors that may affect quality, safety, and patient outcomes will be described.